Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Immunome Inc

Company price
15.69 USD 0.00(0%)
Last update at 2026-11-20T21:00:00Z
VOLUME
1056097
Market Cap
876.75M

Momentum Score

…

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
15.55
Low
16.73
High
52 Week Price Range
4.50
Low
30.96
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Immunome, Inc. is a clinical-stage biotechnology company that discovers and develops human antibody therapeutics using a memory B‑cell discovery platform focused on oncology and immune-driven diseases. Long-term growth drivers include advancement of clinical-stage candidates, broader application of its antibody discovery technology and potential partnerships or licenses that could accelerate development. Investors may find exposure to a pipeline that could generate value from clinical milestones and technology licensing of interest.
Principal investment risks include clinical and regulatory failure for lead candidates, ongoing cash burn and the need for additional financing, and intense competition from larger, better-funded biologics developers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
15.69
Dividend Yield
-
Revenue TTM
14.02M
Revenue Per Share
0.71
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-156.45%
Net Debt
-97.03M
ROCE
-29.12%
Diluted EPS TTM
-18.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -36.90M -24.71M -17.84M -10.44M -7.84M
Net income -37.51M -24.47M -17.12M -10.55M -7.84M
Selling general administrative 13.63M 11.09M 4.78M 1.52M 0.87M
Reconciled depreciation 0.63M 0.76M 0.76M 0.61M 0.52M
Ebit -36.90M -25.20M -13.02M -10.35M -7.70M
Ebitda -36.27M -24.70M -12.26M -9.72M -7.18M
Depreciation and amortization 0.63M 0.50M 0.76M 0.62M 0.52M
Non operating income net other 0.01M - - - -
Operating income -36.90M -25.20M -12.26M -10.35M -7.74M
Other operating expenses 36.90M 25.20M 12.26M 10.35M 7.74M
Interest expense 0.01M 0.01M 0.04M 0.11M 0.14M
Interest income - - 0.00M 0.01M 0.04M
Net interest income 0.01M -0.01M -0.04M -0.10M -0.10M
Income tax expense 0.62M -0.24M -0.72M 0.11M 0.04M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 36.90M 25.20M 12.26M 10.35M 7.74M
Total other income expense net 0.01M 0.49M -5.58M -0.10M -0.10M
Net income from continuing ops -36.90M -24.71M -17.84M -10.44M -7.84M
Net income applicable to common shares -37.52M -24.71M -17.84M -10.44M -7.84M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 148.54M 24.05M 57.92M 44.52M 5.06M
Other current assets 6.27M 2.33M 7.41M 3.13M 0.58M
Total liab 28.66M 7.39M 9.74M 3.18M 40.69M
Total stockholder equity 119.88M 16.65M 48.19M 41.34M -35.63M
Deferred long term liab - 0.33M 0.33M - -
Other current liab 7.71M 4.64M 6.65M 1.37M 0.67M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -222.81M -116.00M -79.11M -54.39M -36.56M
Other liab - - 0.01M 0.01M 0.02M
Other assets 0.00M 0.43M 0.43M 0.10M 0.24M
Cash 98.68M 20.32M 49.23M 39.77M 2.54M
Total current liabilities 21.83M 7.33M 9.73M 3.04M 1.67M
Current deferred revenue 10.49M - - - -
Net debt -97.03M -20.03M -49.23M -39.15M -1.98M
Short term debt 0.31M 0.29M - 0.48M 0.45M
Short long term debt - - - 0.48M 0.21M
Short long term debt total 1.65M 0.29M - 0.61M 0.56M
Other stockholder equity 342.66M 132.65M 127.29M 95.74M 0.93M
Property plant equipment - 0.68M 0.85M 1.53M 1.70M
Total current assets 144.70M 22.65M 56.64M 42.89M 3.12M
Net tangible assets - 16.65M 48.19M 41.34M -35.63M
Short term investments 39.46M - - - -
Net receivables 0.29M 0.85M 4.31M 0.90M -
Long term debt - - - 0.13M 0.11M
Inventory - -0.85M -4.31M - -
Accounts payable 3.31M 2.40M 3.08M 1.19M 0.55M
Accumulated other comprehensive income 0.02M - -57.92M -44.52M -1.52M
Common stock total equity - 0.00M - 0.00M -
Retained earnings total equity - -116.00M - -54.39M -
Non currrent assets other 0.10M 0.43M 0.43M 0.10M 0.24M
Non current assets total 3.84M 1.40M 1.29M 1.63M 1.94M
Capital lease obligations 1.65M 0.29M - 0.00M 0.24M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.25M -0.08M -0.59M -0.23M -0.23M
Change to liabilities -2.83M 1.78M 0.50M 0.07M 0.15M
Total cashflows from investing activities -0.25M -0.08M -0.59M -0.23M -0.23M
Net borrowings 0.49M -0.11M 0.05M -0.61M -0.55M
Total cash from financing activities 0.03M 27.77M 49.94M 10.77M -0.55M
Change to operating activities 2.92M 1.00M -1.71M 0.14M -0.25M
Net income -36.90M -24.71M -17.84M -10.44M -7.84M
Change in cash -28.91M 9.46M 37.22M 0.94M -8.19M
Begin period cash flow 49.33M 39.87M 2.64M 1.70M 9.89M
End period cash flow 20.42M 49.33M 39.87M 2.64M 1.70M
Total cash from operating activities -28.69M -18.23M -12.13M -9.60M -7.41M
Issuance of capital stock 0.00M 27.23M 55.90M 4.62M 0.00M
Depreciation 0.63M 0.76M 0.76M 0.61M 0.52M
Sale purchase of stock 0.03M - 55.87M -0.04M 0.00M
Other cashflows from financing activities -0.25M 0.66M 5.54M 11.42M -0.23M
Change to netincome 5.33M 2.95M 6.16M 0.02M 0.02M
Capital expenditures 0.25M 0.08M 0.59M 0.23M 0.23M
Cash flows other operating 5.28M - -2.41M - -
Cash and cash equivalents changes -28.91M - 37.22M - -
Change in working capital 2.24M 2.78M -1.21M 0.21M -0.10M
Stock based compensation 5.33M 3.45M 0.62M 0.01M 0.01M
Other non cash items - 0.00M -0.00M 0.00M 0.01M
Free cash flow -28.94M -18.30M -12.72M -9.83M -7.63M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IMNM
Immunome Inc
-
-%
15.69 - - 87.64 10.26 77.74 -38.92
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Immunome Inc

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

18702 N. Creek Parkway, Bothell, WA, United States, 98011

610-321-3700

55

Name Title Year Born
Dr. Purnanand Duddu Sarma Ph.D. Pres, CEO & Director 1965
Ms. Corleen M. Roche Chief Financial Officer 1966
Dr. Dennis H. Giesing Ph.D. Chief Devel. Officer 1952
Dr. Scott K. Dessain M.D., Ph.D. Co-founder & Chairman of the Scientific Advisory Board NA
Dr. Matthew K. Robinson Ph.D. Chief Technology Officer NA
Dr. Michael J. Morin Ph.D. Chief Scientist 1955
Ms. Sandra G. Stoneman Esq. Chief Legal Officer, Gen. Counsel & Corp. Sec. 1973
Mr. Robert Lapetina VP of Fin. & Corp. Controller NA
Dr. Clay B. Siegall Ph.D. President, CEO & Chairman 1961
Mr. Max Rosett Interim CFO & Executive VP of Operations 1990

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…